The stock value of Quantum BioPharma Ltd. (NASDAQ: QNTM) saw a significant increase, rising 22.56% to $36.99 as of the previous check. The upward trend follows the publication of a comprehensive analytical report by Singular Research, a respectable independent research firm that specializes in small-cap companies.
The research highlighted Quantum BioPharma’s ongoing advancements in its state-of-the-art pharmaceutical pipeline aimed at disorders connected to the nervous system and alcohol.
Clinical Milestones Indicate Important Advancements
The business is still making progress in its clinical development initiatives, especially with the FSD202 program. A Phase 2 clinical research assessing FSD202 in individuals with Idiopathic Mast Cell Activation Syndrome (MCAS) has been approved by the Human Research Ethics Committee (HREC).
In order to quantify the reduction in daily pain intensity—a crucial first step in treating this presently incurable condition—60 patients will be included in the randomized, double-blind experiment over a 56-day period.
At the same time, Quantum is speeding up the Lucid-MS program. For Lucid-21-302, the company anticipates submitting an Investigational New Drug (IND) application to the FDA in Q4 2025. This exclusive substance provides a non-immunomodulatory method of treating progressive Multiple Sclerosis.
To support this endeavor, a PET imaging study with Massachusetts General Hospital has already commenced, with the first patient scanned, potentially validating the drug’s mechanism of action.
Strategic Expansion and Investment Initiatives
Quantum’s subsidiary, Celly Nutrition, has been rebranded as Unbuzzd Wellness Inc. and retained MNP LLP for PCAOB audits, signaling readiness for a potential initial public offering. The company aims to market “unbuzzd”—a natural product that accelerates alcohol metabolism. Quantum retains a 20.11% ownership stake in Unbuzzd Wellness.
Additionally, the company has diversified its treasury, increasing Bitcoin holdings to $5 million. It also unveiled plans to issue Contingent Value Rights (CVRs) to shareholders tied to litigation proceeds from an ongoing case, potentially exceeding $700 million.
